Penny Asbell

ARMOR surveillance study update gives current insights on antibiotic resistance for clinical ocular isolatesThe most recent analyses of data from the ARMOR (Antibiotic Resistance Monitoring in Ocular micRoorganisms) Surveillance Program can guide clinicians choosing antibiotic therapy for initial empiric therapy and infection prophylaxis. The information also reinforces the importance of prudent antibiotic prescribing to limit the development of bacterial resistance to existing options, according to Penny Asbell, MD.
Webinar: The ARMOR study five-year surveillance resultsWatch as Penny Asbell, MD, talks about antibiotic resistance in a webinar titled: The ARMOR Study Five-Year Surveillance Results.
Clinical advice from the latest ARMOR study updateIn the most recent update from the ARMOR study, Penny Asbell, MD, FACS, MBA, explained that clinicians must choose their antibiotics carefully.
Dry eye therapies continue to emergeLooking to the future of dry eye management, Penny Asbell, MD, said she sees multiple examples of hope: a new device, trial findings, and emerging FDA and non-FDA approved therapeutics.